New Developments in Myeloma Treatment and Response Assessment

Kraeber-Bodéré, Françoise; Jamet, Bastien; Bezzi, Davide; Zamagni, Elena; Moreau, Philippe; Nanni, Cristina

doi:10.2967/jnumed.122.264972

Cited by 7 publications

(3 citation statements)

References 156 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This condition correlated with shorter PFS [14]. Furthermore, double negativity (both in the BM and at PET/CT) can be considerate a surrogate for outcome prediction, while double positivity or discordant results between the 2 methods should be considered for categorizing patients in specific prognostic classes [12].…”

Section: Focus On Plasma Cellsmentioning

confidence: 99%

“…In fact, tumor cells increase glucose uptake and lactate production (Warburg Effect) [11]. Reduction in focal lesions (FLs) metabolism has shown to have a prognostic meaning and a complete normalization of PET/CT findings after induction therapy is associated with higher PFS and OS [12]. In a retrospective study of both ASCT-eligible and ineligible patients, PET/CT was evaluated at diagnosis and after treatment.…”

Section: Focus On Plasma Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Fazio,

Del Fabro,

Parrinello

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Multiple myeloma is a chronic hematologic malignancy that obstinately tends to relapse. Basic research has made giant strides in better characterizing the molecular mechanisms of the disease. The results have led to the manufacturing of new, revolutionary drugs which have been widely tested in clinical trials. These drugs have been approved and are now part of the therapeutic armamentarium. As a consequence, it is essential to combine what we know from clinical trials with real-world data in order to improve therapeutic strategies. Starting with this premise, our review aims to describe the currently employed regimens in multiple myeloma and compare clinical trials with real-life experiences. We also intend to put a spotlight on promising therapies such as T-cell engagers and chimeric antigen receptor T-cells (CAR-T) which are proving to be effective in changing the course of advanced-stage disease.

show abstract

Section: Focus On Plasma Cellsmentioning

confidence: 99%

Section: Focus On Plasma Cellsmentioning

confidence: 99%

Multiple Myeloma in 2023 Ways: From Trials to Real Life

Fazio,

Del Fabro,

Parrinello

et al. 2023

Current Oncology

View full text Add to dashboard Cite

show abstract

“…There have been major breakthroughs in the field of MM treatment that have significantly improved the prognosis of patients. Despite these advances, the disease is still incurable, and relapses are common [9].…”

Section: Introductionmentioning

confidence: 99%

Relapsed IgA Multiple Myeloma as Testicular Plasmacytoma after Quadrable Novel Therapy and Autologous Stem Cell Transplant: A Rare Case Report and Literature Review

Abdulgayoom,

Soliman,

Helmy

et al. 2024

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: Multiple myeloma (MM) is a clonal neoplasm of plasma cells that may manifest as an extramedullary disease in rare cases. Case Report: In this case report, we present the rare occurrence of testicular relapse in a 39-year-old patient with IgA MM after 3 years of remission. We discuss the clinical course and management of this unusual presentation and provide a comprehensive literature review of testicular involvement by MM. Conclusion: Despite advances in MM treatment, relapse remains common, highlighting the importance of careful follow-up and timely detection of disease recurrence at atypical sites. This case highlights the need for further research to standardize the diagnosis and treatment of testicular MM.

show abstract